• Medical_Professionals
• Medical_students
• Nurses

The 62nd Annual SSC Meeting of the ISTH will be devoted to the discussion of diagnostic standards, disease nomenclature and classification, and the latest research on bleeding and thrombotic disorders. Topics center around the work of each of the SSC Subcommittees. Continuing the tradition of offering dedicated educational and plenary sessions to complement the in-depth presentations of the work in progress by the SSC subcommittees and working groups, SSC 2016 is a must-attend scientific event in the field of thrombosis and hemostasis, and your participation and involvement is vital to its success.

Jean-François Schved, SSC 2016 Meeting President

Montpellier, France

Montpellier is the very definition of the Mediterranean city. With its rich historical heritage and idyllic location just a few kilometers from the sea, Montpellier is a key international city for business tourism.

A lively city in the heart of the Languedoc-Roussillon region, Montpellier is vibrant, elegant and artistic. People are drawn here by the city's rich past, former and contemporary glory, intense cultural life and youthful feel. Its sunny climate and well-preserved historical environment are second to none, nestled between the sea, vineyards and mountain landscapes.

EUR

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Le Corum Conference Centre will serve as the SSC 2016 meeting and exhibition venue. Located in the heart of Montpellier, Le Corum is the perfect place to host any event.

As one of France's top conference centers, it also houses the Berlioz Opera House, which is known for its outstanding acoustics. The building opened in 1988 and is covered in slabs of pink marble.

The Le Corum Conference Centre is located at Esplanade Charles De Gaulle, BP 2220, 34000 Montpellier, France. 

Submission Info

Delegates who would like to present their work at the meeting, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee. 

Please find the full Abstract Submission Guidelines below:

Important Dates:

Abstract submission opens: December 1, 2015

Submission deadline: February 1, 2016, 11:59 p.m. Eastern Standard Time

Abstracts received after the deadline will not be accepted! 

Notifications to submitters: March 2016

Technical Requirements:

The internet abstract submission system works best with Internet Explorer 7.0 or higher or Mozilla Firefox 3.0 or higher. Cookies and JavaScript need to be enabled.

General:

Abstracts can only be submitted online via the abstract submission form that can be found in the section "abstracts” on the official ISTH 2016 SSC website. Abstracts sent by post or email will not be accepted. No exceptions will be made.  The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

Main Topics:

Platelets (Basic & Clinical)

Coagulation Factors (Basic)

Thrombotic Disorders (Clinical)

Bleeding Disorders (Clinical)

Fibrinolysis and Proteolysis (Basic)

Vascular Biology

Hematopoiesis 

You will be asked to define which SSC Subcommittees and working groups your abstract most aligns with from the following list:

Section One - Platelets: 

Signal transduction in platelets

Molecular basis of inherited or acquired platelet disorders

Clinical aspects of Inherited platelet disorders

Clinical aspects of Acquired platelet disorders 

Anti-platelet therapy

Platelets in transfusion medicine

Experimental models

 Section Two - Coagulation Factors

Coagulation pathways

Contact phase activation

Anticoagulant pathway

Exogenous hemostatic factors

Fibrinogen and other factors

Experimental models

Section Three - Thrombotic Disorders  

Deep vein thrombosis and pulmonary embolism

Arterial Thromboembolism

Genetic determinants and epidemiology

Anti-phospholipid syndrome

Disseminated intravascular coagulation

Thrombotic disorders in children

Thrombotic disorders in women

Cancer and thrombosis – clinical

Cancer and thrombosis – basic science

Antithrombotic therapy

Laboratory tests

Experimental models

TTP

Hemostatic assays

Biorheology/Biophysics

 Section Four - Bleeding Disorders  

von Willebrand Disease

Laboratory tests

Experimental models

Haemophilia

Inhibitors

Other inherited bleeding disorders

Acquired bleeding disorders

Bleeding disorders in children

Bleeding disorders in women

Innovative therapies for bleeding disorders

Laboratory tests

Experimental models

Section Five - Fibrinolysis and Proteolysis

Plasminogen and plasminogen activators

Plasminogen activator inhibitors

PA system in organ-specific disorders

Fibrinogen and fibrin

New thrombolytic agents and drug design

Laboratory tests

Experimental models

 Section Six - Vascular Biology

Atherosclerosis

Endothelial cells

Inflammatory cells and cytokines

Vascular development

Endothelial Progenitor Cells

Experimental models

Microparticles/extracellular vesicles

Section Seven - Hematopoiesis

Megakaryocyte biology

Progenitor Cells and Stem Cells

Gene Therapy

Overall Guidelines

The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.

Abstracts submitted for ISTH 2016 SSC are embargoed from the time of submission.  This means that the data in the abstract cannot be submitted to other meetings once submitted for the ISTH 2016 SSC meeting. Likewise, abstracts must contain original information, not submitted, published or presented elsewhere prior to submission.

The first / presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

Abstracts that have been submitted to a previous conference in the same specialty, published or unpublished, will not be accepted.

The Scientific Committee retains the right to reject abstracts containing previously submitted or presented data as they see fit.

All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.

If off-label use of drugs was involved in the study, please state this clearly.

If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.

Please indicate the funding agency of your work if applicable.

The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.

Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected.

Similarly, do not submit a copy or close copy of an abstract under more than 1 topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.

Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.

For standardization, the acceptable length of the abstract is a maximum of 2,000 characters including non-visible characters, such as spaces and line breaks. This does not include the author’s details, titles, keywords, tables and graphs.

Abstracts can be saved in "Draft” status to be re-edited and modified until the submission deadline (February 1, 2016, 11:59 EST). Therefore, the submitter will be required to create a user account.

The submitted / draft abstracts cannot be edited after the submission deadline.

Abstracts fulfilling all criteria can be saved and submitted. You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.

Only abstracts that have been submitted properly will be considered for the meeting.

The abstract should be structured into the following sections:

A title which clearly indicates the nature of the investigation

Background

Aims

Methods, which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study

Results, which should contain objective data to answer the scientific question(s). One table may be inserted into this section.

Conclusion (or Conclusions) which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

Keywords: please choose four keywords, these will NOT count towards the 2,000 character count limit. 

Images and graphs may be inserted with a maximum size of 600 x 800 pixels

Tables are allowed with a maximum size of 10 columns x 10 rows. Characters in your table will NOT count towards your 2,000 character count.

Adding Co-authors: please fill out the family names, first names, and institute, city, country and email addresses of the co-authors.

As at previous ISTH SSC Meetings, industry partners will have the opportunity to sponsor symposia as well as present their products and solutions as part of the industry exhibition.

A total of nine (9) Lunch Time Symposia slots are available (3 per day) and three (3) Technical Session opportunities will be offered.

As the Manual outlines, ISTH SSC 2016 will also offer many additional ways for industry partners to increase their visibility, show their commitment to the field, and support the meeting.

The ISTH recognizes the important role its corporate partners play as participating and contributing stakeholders, and welcomes ideas on other support opportunities and input from partners to develop a package to meet their needs.

Why should you participate as an exhibitor or sponsor?

Exhibiting at or supporting the ISTH’s SSC 2016 Meeting ensures your presence at the foremost international conference devoted to thrombosis and haemostasis. As a corporate partner, you will reach a diverse and influential group of scientists, researchers and clinicians from the world’s top institutions and have the opportunity to increase your company’s visibility, build your network and ensure your commitment, discoveries, products and solutions are best presented to a global audience of decision makers and key opinion leaders.

Your participation and partnership as a supporter will associate your brand with innovation and a commitment to leadership development, scientific discoveries and well-informed standardization in our field.

Through your support or exhibition engagement, you will:

Engage and interact with over 1,500 scientists and clinicians who are decision makers and thought leaders in basic science, laboratory and clinical practice from around the world

Partner with the leading international Society in the field of thrombosis and hemostasis and its Scientific and Standardization Committee (SSC), which has set standards in laboratory and clinical science for over 60 years

Engage with the next generation of key opinion leaders

Create meaningful partnerships and awareness about your products, services and solutions

Learn about the challenges as well as proposed approaches to today’s pressing scientific, diagnostic and clinical problems

Actively participate in the discussions about the translation of the latest science into clinical evaluation and applications

Participate in a meeting environment conducive to scientific exchange and dialogue about the latest products and services available to our professional community

Support the mission of the ISTH to advance the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders

Order forms due dates for priority consideration:

We invite order forms and confirmation of support options according to our ISTH Priority Point System, with the following deadlines set for 3 rank groups:

  --  Top 10 Partners:    July 31

  --  11 – 25 Partners:August 17

  --  >25 and unranked Partners:August 31

For information about symposia, sponsor options and exhibit space, please contact:

Mr. Thomas Reiser 

Executive Director

ISTH Headquarters 

610 Jones Ferry Road, Suite 205 

Carrboro, NC 27510 USA 

T: +1 919 929 3807

tom_reiser@isth.org

ISTH Contact Information

ISTH Headquarters

610 Jones Ferry Road, Suite 205 Carrboro, NC 27510 USA

Phone: +1 919 929-3807 | Fax: +1 919 929-3935